Ftse Mib
34.777,46
0,83%
DAX
18.642,87
0,86%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
68.901,37
1,71%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Foghorn Therapeutics Inc (FHTX) Foghorn Therapeutics Inc (FHTX) Notizie

FHTX

Foghorn Therapeutics (FHTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FHTX
DataOraFonteTitoloSimboloCompagnia
28/05/202413:00GlobeNewswire Inc.Foghorn Therapeutics to Participate in Upcoming Investor Conferences in JuneNASDAQ:FHTXFoghorn Therapeutics Inc
23/05/202413:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FHTXFoghorn Therapeutics Inc
23/05/202400:21GlobeNewswire Inc.Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance PipelineNASDAQ:FHTXFoghorn Therapeutics Inc
20/05/202422:31Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:FHTXFoghorn Therapeutics Inc
06/05/202413:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FHTXFoghorn Therapeutics Inc
06/05/202413:03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FHTXFoghorn Therapeutics Inc
07/03/202413:09Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:FHTXFoghorn Therapeutics Inc
25/01/202422:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FHTXFoghorn Therapeutics Inc
28/11/202301:01PR Newswire (US)Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science LeadersNASDAQ:FHTXFoghorn Therapeutics Inc
21/11/202312:00PR Newswire (US)Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsNASDAQ:FHTXFoghorn Therapeutics Inc
01/11/202315:30PR Newswire (US)Flagship Pioneering Launches Pioneering IntelligenceNASDAQ:FHTXFoghorn Therapeutics Inc
11/09/202312:30PR Newswire (US)Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerNASDAQ:FHTXFoghorn Therapeutics Inc
05/09/202314:00GlobeNewswire Inc.Foghorn Therapeutics Announces Participation in Upcoming Investor ConferencesNASDAQ:FHTXFoghorn Therapeutics Inc
31/08/202313:00GlobeNewswire Inc.Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AMLNASDAQ:FHTXFoghorn Therapeutics Inc
29/08/202315:00PR Newswire (US)Invaio achieves first registration for citrus greening solution featuring Trecise™ technologyNASDAQ:FHTXFoghorn Therapeutics Inc
08/08/202313:00GlobeNewswire Inc.Foghorn Therapeutics Announces Chief Medical Officer SuccessionNASDAQ:FHTXFoghorn Therapeutics Inc
04/08/202313:00GlobeNewswire Inc.Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate UpdateNASDAQ:FHTXFoghorn Therapeutics Inc
28/06/202313:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FHTXFoghorn Therapeutics Inc
28/06/202313:00GlobeNewswire Inc.Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal MelanomaNASDAQ:FHTXFoghorn Therapeutics Inc
05/06/202314:07Dow Jones NewsFoghorn Therapeutics Shares Rally Premarket as FDA Lifts Clinical HoldNASDAQ:FHTXFoghorn Therapeutics Inc
16/05/202312:00PR Newswire (US)Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of BiomimicryNASDAQ:FHTXFoghorn Therapeutics Inc
08/05/202313:07Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:FHTXFoghorn Therapeutics Inc
08/05/202313:06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:FHTXFoghorn Therapeutics Inc
28/04/202322:07Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:FHTXFoghorn Therapeutics Inc
28/04/202322:01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:FHTXFoghorn Therapeutics Inc
22/02/202322:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FHTXFoghorn Therapeutics Inc
09/02/202317:02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:FHTXFoghorn Therapeutics Inc
21/11/202217:35TipRanksMorgan Stanley Keeps Their Hold Rating on Foghorn Therapeutics (FHTX)NASDAQ:FHTXFoghorn Therapeutics Inc
09/11/202212:25TipRanksH.C. Wainwright Sticks to Its Buy Rating for Foghorn Therapeutics (FHTX)NASDAQ:FHTXFoghorn Therapeutics Inc
31/10/202221:02Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:FHTXFoghorn Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FHTX

La tua Cronologia

NASDAQ
ATNFW
180 Life Sciences
BMF
DIFF29F30
DIFF29F30 - 01/2029
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network